Vaxxas Pty Ltd has secured approximately $90 million in financing to advance its revolutionary high-density microarray patch technology for needle-free vaccine delivery.

Information on the Target

Vaxxas Pty Ltd is a clinical-stage biotechnology company based in Brisbane, Australia, specialized in developing its innovative high-density microarray patch (HD-MAP) for needle-free vaccine delivery. This pioneering technology aims to improve vaccine accessibility by enabling self-administration, significantly reducing the cold-chain requirements associated with traditional vaccines. Vaxxas has successfully conducted clinical trials involving over 750 participants, illustrating the safety, tolerability, and robust immune responses that its technology can elicit across various vaccine types, including live attenuated, protein subunit, and mRNA vaccines.

Having raised over $300 million to date, nearly $160 million of which has positively impacted the Australian economy, Vaxxas's mission is to disrupt the global vaccine market, enhancing access, cost-effectiveness, and coverage rates. The most recent financing round, which attracted approximately $90 million, underscores the growing confidence in Vaxxas's innovative approach to vaccine delivery.

Industry Overview in Australia

The biotechnology sector in Australia is a rapidly expanding industry, supported by strong governmental initiatives, a robust research framework, and increased private investment. Australia’s biotech landscape is marked by a surge in clini